<DOC>
	<DOCNO>NCT01078662</DOCNO>
	<brief_summary>To assess efficacy oral olaparib patient advance cancer confirm genetic BRCA1 and/or BRCA2 mutation , assessment tumour response</brief_summary>
	<brief_title>Open Label Study Assess Efficacy Safety Olaparib Confirmed Genetic BRCA1 BRCA2 Mutation Pats</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Confirmed document deleterious suspect deleterious BRCA mutation . ( The presence lossoffunction germline mutation BRCA1 and/or BRCA2 gene must confirm prior consent accord local practice ) . Confirmed malignant solid tumour standard treatment exists At least one lesion ( measurable and/or non measurable ) baseline accurately assess CT/MRI suitable repeat assessment follow visit Any previous treatment PARP inhibitor , include olaparib Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication Patients receive systematic chemotherapy , radiotherapy ( except palliative reason ) within 2 week last dose prior study treatment ( long period depend defined characteristic agent use )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>olaparib</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>genetic BRCA1 mutation</keyword>
	<keyword>BRCA2 mutation</keyword>
	<keyword>solid tumour refractory</keyword>
</DOC>